Why the study?
Does intracoronary infusion of functionally competent bone marrow-derived mononuclear progenitor cells improve survival and reduce natriuretic peptide levels in patients with chronic postinfarction heart failure?
Does intracoronary infusion of functionally competent bone marrow-derived mononuclear progenitor cells improve survival and reduce natriuretic peptide levels in patients with chronic postinfarction heart failure?
Intracoronary infusion of functionally competent bone marrow-derived progenitor cells is associated with reduced natriuretic peptide levels and improved survival in patients with chronic postinfarction heart failure.
No takes yet. Share an insight, caveat, or question.
Associated mortality reduction in high-NT-proBNP patients supports further progenitor cell investigation; leaves open efficacy in randomized trials.
Aßmus et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: